drugset
drugset / Trial / NCT06859333

Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

NCT06859333 ↗

Phase 1 Recruiting 36 enrolled Valenta Pharm JSC
Non-randomizedSequentialSingle-blindOther

Summary

This is a Single Center, First-in-human Study of Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single and Multiple Doses of Ingavirin Forte, Capsules in Healthy Volunteers.

Timeline

Start
2025-01-13
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid Unknown 5 mg Oral
Subject N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid Unknown 10 mg Oral
Subject N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid Unknown 20 mg Oral
Subject imidazolylethylamide of pentanedioic acid Unknown 90 mg Oral

Indications

influenza